SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the recipient of some unusual options trading activity on Monday. Stock investors bought 48,643 put options on the stock. This is an increase of 19% compared to the average daily volume of 40,961 put options.
Institutional Investors Weigh In On SELLAS Life Sciences Group
Hedge funds have recently bought and sold shares of the business. Dagco Inc. grew its position in shares of SELLAS Life Sciences Group by 8.4% in the third quarter. Dagco Inc. now owns 1,336,449 shares of the company’s stock valued at $16,452,000 after purchasing an additional 104,016 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of SELLAS Life Sciences Group by 535.7% in the first quarter. Bank of America Corp DE now owns 641,683 shares of the company’s stock valued at $2,714,000 after purchasing an additional 540,748 shares during the last quarter. Wellington Management Group LLP lifted its position in SELLAS Life Sciences Group by 73.2% during the second quarter. Wellington Management Group LLP now owns 597,309 shares of the company’s stock worth $8,816,000 after buying an additional 252,531 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in SELLAS Life Sciences Group during the second quarter worth approximately $7,823,000. Finally, Marshall Wace LLP purchased a new position in SELLAS Life Sciences Group during the third quarter worth approximately $3,494,000. Hedge funds and other institutional investors own 17.38% of the company’s stock.
SELLAS Life Sciences Group Stock Down 4.2%
SLS traded down $0.33 during mid-day trading on Monday, reaching $7.53. 3,178,609 shares of the company traded hands, compared to its average volume of 7,843,897. The stock has a market capitalization of $1.52 billion, a P/E ratio of -38.10 and a beta of 2.73. The company’s fifty day moving average price is $11.03 and its 200-day moving average price is $8.77. SELLAS Life Sciences Group has a 52-week low of $1.39 and a 52-week high of $15.88.
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05).
Wall Street Analyst Weigh In
Several analysts have commented on SLS shares. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $10.00.
View Our Latest Stock Analysis on SELLAS Life Sciences Group
SELLAS Life Sciences Group Company Profile
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.
Featured Articles
- Five stocks we like better than SELLAS Life Sciences Group
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
